Leake J F, Rader J S, Woodruff J D, Rosenshein N B
Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, Maryland 21205.
Gynecol Oncol. 1991 Aug;42(2):124-30. doi: 10.1016/0090-8258(91)90331-x.
A comprehensive understanding of retroperitoneal lymphatic involvement is lacking in tumors of low malignant potential. This study was undertaken to evaluate retroperitoneal lymphatic involvement in patients with ovarian tumors of low malignant potential. One hundred seventy-one patients were diagnosed with epithelial ovarian tumors of low malignant potential between 1979 and 1989. Thirty-four (20%) of these patients underwent surgical staging which included lymph node sampling. The stage distribution was Stage I in 17 patients (50%), Stage II in 4 patients (12%), and Stage III in 13 patients (38%). The histology of the tumors was serous in 26 patients (76%), mucinous in 7 patients (21%), and seromucinous in 1 patient (3%). The incidence of retroperitoneal lymphatic involvement was 21%. The occurrence of positive pelvic and para-aortic nodes was 17 and 18%, respectively. Patients with localized intraperitoneal disease were upstaged in 22% of the cases based on retroperitoneal lymphatic involvement. Four of twenty-one patients (19%) with intraperitoneal disease confined to the ovary and two of six patients (33%) with intraperitoneal disease confined to the pelvis were upstaged to Stage III as a result of retroperitoneal lymphatic disease. Although the nodal status of patients did not significantly affect survival, those patients with localized intraperitoneal disease and nodal involvement had a higher incidence of recurrence which was statistically significant (P = 0.025). Accordingly, retroperitoneal lymph node sampling at the time of initial laparotomy may provide valuable prognostic information regarding recurrence in patients with tumors of low malignant potential.
对于低恶性潜能肿瘤,目前缺乏对腹膜后淋巴结受累情况的全面了解。本研究旨在评估低恶性潜能卵巢肿瘤患者的腹膜后淋巴结受累情况。1979年至1989年间,171例患者被诊断为低恶性潜能上皮性卵巢肿瘤。其中34例(20%)患者接受了包括淋巴结采样在内的手术分期。分期分布为:17例(50%)为Ⅰ期,4例(12%)为Ⅱ期,13例(38%)为Ⅲ期。肿瘤组织学类型为浆液性26例(76%),黏液性7例(21%),浆液黏液性1例(3%)。腹膜后淋巴结受累发生率为21%。盆腔和腹主动脉旁淋巴结阳性发生率分别为17%和18%。根据腹膜后淋巴结受累情况,22%局限于腹腔内疾病的患者分期上调。21例局限于卵巢的腹腔内疾病患者中有4例(19%),6例局限于盆腔的腹腔内疾病患者中有2例(33%)因腹膜后淋巴结疾病分期上调至Ⅲ期。虽然患者的淋巴结状态对生存率无显著影响,但局限于腹腔内疾病且有淋巴结受累的患者复发率较高,具有统计学意义(P = 0.025)。因此,初次剖腹手术时进行腹膜后淋巴结采样可能为低恶性潜能肿瘤患者的复发提供有价值的预后信息。